Ipamorelin/Tesamorelin

Ipamorelin + Tesamorelin Blend by Dragon Pharma

The Ipamorelin + Tesamorelin blend combines Dragon Pharma's selective GHRP with the only FDA-approved GHRH analogue in a single 10mg vial. This is a fat-loss-focused GH secretagogue stack — pairing Ipamorelin's clean nocturnal GH pulse amplification with Tesamorelin's Phase III clinical data showing 15-20% visceral fat reduction over 26 weeks.

Also searched as: Ipamorelin Tesamorelin blend, Ipa Tesa peptide stack, GHRP GHRH fat loss blend, Ipamorelin Tesamorelin Dragon Pharma.

Why Ipamorelin + Tesamorelin — Not Just Any GHRH + GHRP

This blend is specifically designed around fat loss as the primary goal — and the choice of Tesamorelin as the GHRH component (rather than CJC-1295) is deliberate and clinically significant:

The data gap is clear: if visceral fat reduction is the priority, Tesamorelin has clinical trial evidence; CJC-1295 does not. When Dragon Pharma formulated this specific blend, the intention was a fat-loss-optimised stack — Tesamorelin's clinical fat reduction data paired with Ipamorelin's cortisol-free GH pulse amplification for body recomposition.

Why Ipamorelin Is the Ideal GHRP Partner for Tesamorelin

Tesamorelin could theoretically be paired with any GHRP, but Ipamorelin's properties make it the most suitable partner specifically:

• No cortisol elevation — during fat loss protocols, elevated cortisol drives catabolism and visceral fat accumulation; the other GHRPs (GHRP-2, GHRP-6) would partially counteract the fat-loss goal through cortisol elevation
• Matched short half-lives (~26 min for Tesamorelin, ~2 hours for Ipamorelin) — both can be co-administered in the same injection for simultaneous receptor activation
• No appetite stimulation — GHRP-6's pronounced appetite effect would compromise caloric control during a fat-loss phase
• Clean hormonal profile — no prolactin, ACTH or other hormonal disruption alongside the stack

Effects and Benefits

• Synergistic GH release from GHRH + GHRP dual receptor activation
• Visceral fat reduction supported by Phase III clinical data for the Tesamorelin component
• Ipamorelin's clean nocturnal GH pulse amplification without cortisol elevation
• Improved sleep quality from optimised nocturnal GH secretion
• No suppression of natural testosterone — does not require Post Cycle Therapy

Dosage and Administration

Both components have short half-lives, requiring daily dosing — unlike CJC-1295 DAC which allows weekly injections. Pre-sleep dosing on an empty stomach remains the most important injection for maximum nocturnal GH pulse amplification. At 10mg total vial content with 200mcg per injection, a single vial provides approximately 25 injections at once-daily dosing.